In the AIDP group, the ratio of CD4+/CD8+ T cells (1.85 ± 1.09 vs 1.29 ± 0.80) and the percentage of CD4+CD45RA+ T cells (37.56 ± 9.22 vs 29.10 ± 10.13) increased significantly (p <0.05), while the percentage of CD8+ T (29.60 ± 7.90 vs 35.12 ± 11.94), CD4+CD45RO+ T (57.51 ± 8.45 vs 65.60 ± 10.41), and CD19+ B (12.11 ± 4.58 vs 15.89 ± 3.41) cells significantly decreased (p <0.05) after treatment. Here, CD8A is linked to Guillain-Barre syndrome, familial.